FDA approves Ipsen's Iqirvo for primary biliary cholangitis, ending a 10-year hiatus in new therapies for the rare cholestatic liver disease.

FDA approves Gilead's Livdelzi for primary biliary cholangitis, setting up a contest with Ipsen's recent launch Iqirvo in the second-line setting.